Nuances to precision dosing strategies of targeted cancer medicines

Selecting the dose of a targeted cancer medicine that is most appropriate for a specific individual is a rational approach to maximize therapeutic outcomes and minimize toxicity. There are many different options for optimizing the dose of targeted cancer medicines and the purpose of this review is to provide a comprehensive comparison of the main options explored in prospective studies. Precision initial dose selection of targeted cancer therapies has been minimally explored to date; however, concentration, toxicity, and therapeutic outcome markers are used to guide on‐therapy dose adaption of targeted cancer therapies across several medicines and cancers. While a specific concentration, toxicity, or therapeutic outcome marker commonly dominates an investigated precision on‐therapy dose adaption strategy, greater attention to simultaneously account for exposure, toxicity, therapeutic outcomes, disease status, time since treatment initiation and patient preferences are required for optimal patient outcomes. To enable successful implementation of precision dosing strategies for targeted cancer medicines into clinical practice, future prospective studies aiming to develop strategies should consider these elements in their design.

[1]  Lisa I. Wang,et al.  The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. , 2019, European journal of cancer.

[2]  J. Hasford,et al.  Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV , 2018, Haematologica.

[3]  M. Talpaz,et al.  Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study , 2018, Journal of Hematology & Oncology.

[4]  W. Rathmell,et al.  Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Rowland,et al.  Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries , 2018, European Journal of Clinical Pharmacology.

[6]  D. Kondziolka,et al.  Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M-Mutant Leptomeningeal Lung Adenocarcinoma. , 2017, Journal of Thoracic Oncology.

[7]  T. Hirai,et al.  465PA phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402) , 2017 .

[8]  V. Gebski,et al.  Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring , 2017, Cancer Chemotherapy and Pharmacology.

[9]  G. Peters,et al.  A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors. , 2017 .

[10]  M. Wiese,et al.  The Routine Clinical use of Pharmacogenetic Tests: What it Will Require? , 2017, Pharmaceutical Research.

[11]  B. Rini,et al.  A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Wiese,et al.  Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure , 2017, Expert opinion on drug metabolism & toxicology.

[13]  C. Ryan.  Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma , 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[14]  C. Sima,et al.  Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  A. Eschalier,et al.  Therapeutic drug monitoring and tyrosine kinase inhibitors. , 2016, Oncology letters.

[16]  J. Schellens,et al.  Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients , 2016, Clinical Cancer Research.

[17]  K. Movig,et al.  Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF‐α experience to oncology , 2016, Clinical pharmacology and therapeutics.

[18]  V. Gebski,et al.  Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study , 2016, Clinical Cancer Research.

[19]  J. Cayuela,et al.  Personalized daily doses of imatinib by therapeutic drug monitoring increase the rates of molecular responses in patients with Chronic Myeloid Leukemia - Final results of the randomized Optim imatinib study: Co-028 , 2015 .

[20]  L. Shih,et al.  Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study , 2015 .

[21]  Mellar P. Davis,et al.  Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients , 2015, British Journal of Cancer.

[22]  Y. Hosomi,et al.  A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911. , 2015, European journal of cancer.

[23]  K. Inui,et al.  Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. , 2015, Pharmacology & therapeutics.

[24]  M. Fishman,et al.  Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  H. Guchelaar,et al.  Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib: A Pharmacokinetic Feasibility Study , 2015, Therapeutic drug monitoring.

[26]  C. Sima,et al.  A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers. , 2015 .

[27]  C. Rodríguez-Antona,et al.  Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization. , 2015, Urologic oncology.

[28]  B. Rini,et al.  An alternative titration schedule of axitinib in metastatic renal cell carcinoma. , 2015 .

[29]  M. Kalia,et al.  Biomarkers for personalized oncology: recent advances and future challenges. , 2015, Metabolism: clinical and experimental.

[30]  Harold Varmus,et al.  A new initiative on precision medicine. , 2015, New England Journal of Medicine.

[31]  X. Yao,et al.  A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma. , 2014, Future oncology.

[32]  T. Buclin,et al.  Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial , 2014, Cancer Chemotherapy and Pharmacology.

[33]  L. Gibiansky,et al.  Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL , 2014, CPT: pharmacometrics & systems pharmacology.

[34]  E. Van Cutsem,et al.  Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study , 2014, British Journal of Cancer.

[35]  A. Paci,et al.  Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies. , 2014, European journal of cancer.

[36]  R. Obach,et al.  Relative Contributions of Cytochrome CYP3A4 Versus CYP3A5 for CYP3A-Cleared Drugs Assessed In Vitro Using a CYP3A4-Selective Inactivator (CYP3cide) , 2014, Drug Metabolism and Disposition.

[37]  A. Hagenbeek,et al.  Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis , 2014, Journal of clinical pharmacology.

[38]  C. Liddle,et al.  Effect of toxicity-adjusted dose (TAD) of sunitinib on intra-patient variation of trough levels: A longitudinal study in metastatic renal cell cancer (mRCC). , 2014 .

[39]  S. Sleijfer,et al.  Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours , 2014, British Journal of Cancer.

[40]  J. Schellens,et al.  Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets , 2014, Clinical Pharmacokinetics.

[41]  Pedro Madureira,et al.  EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. , 2013, Pharmacogenomics.

[42]  E. Jonasch,et al.  Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. , 2013, The Lancet. Oncology.

[43]  Martin C. Müller,et al.  Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib , 2013, Annals of Hematology.

[44]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology and Therapeutics.

[45]  U. Zanger,et al.  Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the “Missing Heritability” Problem , 2013, Front. Genet..

[46]  H. Gurney,et al.  Evidence for therapeutic drug monitoring of targeted anticancer therapies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D. Allison,et al.  A Guide to Rational Dosing of Monoclonal Antibodies , 2012, Clinical Pharmacokinetics.

[48]  L. Beckett,et al.  Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors , 2012, Investigational New Drugs.

[49]  R. Amato,et al.  A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma. , 2012, Clinical genitourinary cancer.

[50]  E. Van Cutsem,et al.  Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  C. Lebbé,et al.  Sorafenib in advanced melanoma: a critical role for pharmacokinetics? , 2012, British Journal of Cancer.

[52]  A. Moorman.  The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. , 2012, Blood reviews.

[53]  C. Sternberg,et al.  Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti‐angiogenic treatment , 2012, BJU international.

[54]  M. Climent,et al.  Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. , 2011, The Lancet. Oncology.

[55]  R. Figlin,et al.  Response: Re: Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib , 2011 .

[56]  D. McDermott,et al.  Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma , 2011, Clinical Cancer Research.

[57]  R. Desnick,et al.  Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score , 2011, Clinical pharmacology and therapeutics.

[58]  A. Tolcher,et al.  Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer , 2011, British Journal of Cancer.

[59]  J. Schellens,et al.  Moving towards dose individualization of tyrosine kinase inhibitors. , 2011, Cancer treatment reviews.

[60]  C. Porta,et al.  Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Stefan W Krause,et al.  Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  R. Motzer,et al.  Hand-foot syndrome (HFS) as a potential biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Claude Preudhomme,et al.  Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. , 2010, The New England journal of medicine.

[64]  A. Byars,et al.  Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. , 2010, The New England journal of medicine.

[65]  B. Meibohm,et al.  Population Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.

[66]  J. Schellens,et al.  Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.

[67]  Susan Branford,et al.  Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Giovanni Martinelli,et al.  Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. , 2009, Blood.

[69]  D. Cella,et al.  Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Rene Bruno,et al.  Clinical pharmacokinetics of bevacizumab in patients with solid tumors , 2008, Cancer Chemotherapy and Pharmacology.

[71]  H. Izzedine,et al.  Hypertension as a predictive factor of Sunitinib activity. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  B. Lum,et al.  Rationale for Fixed Dosing of Pertuzumab in Cancer Patients Based on Population Pharmacokinetic Analysis , 2006, Pharmaceutical Research.

[73]  P. Klein,et al.  Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer , 2005, Cancer Chemotherapy and Pharmacology.

[74]  H. Kantarjian,et al.  High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. , 2004, Blood.

[75]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  J. Zonder,et al.  The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[77]  H. Kantarjian,et al.  Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. , 2003, Blood.

[78]  M. Czuczman,et al.  Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  W. Laubender.  Über die Unterdrückbarkeit der Acetylcholin- und Rhodanidkontraktur durch Pyrazolonderivate , 1960 .

[80]  A. Eschalier,et al.  Therapeutic drug monitoring and tyrosine kinase inhibitors ( Review ) , 2016 .

[81]  H. Guchelaar,et al.  Individualized dosing of tyrosine kinase inhibitors: are we there yet? , 2015, Drug discovery today.

[82]  A. Kiss,et al.  Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. , 2014, Urologic oncology.

[83]  V. Haufroid,et al.  CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. , 2013, Pharmacogenomics.

[84]  Honghui Zhou,et al.  PHARMACOKINETICS AND DISPOSITION Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis , 2009 .

[85]  H. Kantarjian,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Result of high-dose imatinib mesylate in patients with Philadelphia chromosome–positive chronic myeloid leukemia after failure of interferon-� , 2022 .